Audentes Therapeutics, Inc

Audentes Therapeutics, Inc (BOLD) related to its sale to Astellas Pharma, Inc. Under the terms of the Agreement, Audentes shareholders will have the right to receive $60.00 in cash for each Audentes common stock owned.

To receive more information regarding the investigation of Audentes Therapeutics, Inc please fill out the form below.